Heart failure affects millions of people worldwide, compounded by limited therapeutic options and a severe shortage of donor organs. Despite this, heart transplantation still retains the “gold standard” status for the treatment of end-stage heart failure, although globally, only about 6,000 heart transplants are performed annually. Mechanical Circulatory Support Devices (like the BiVACOR TAH) ensure the stabilization of patients’ conditions while awaiting a donor organ.
The titanium artificial heart was created by biomedical engineer Dr. Daniel Timms. Unlike conventional mechanical pumps, BiVACOR uses a single moving mechanism: a rotating part (rotor) floating on a magnet. This new design provides long-lasting durability and is less damaging to blood cells. Thanks to this construction, continuous blood circulation is achieved, which fully replaces the function of both ventricles of the heart.
An Australian patient (one of six patients) was discharged from the hospital and continued to live independently in a nearby residence until a donor heart transplant. This is the first clinical case where a patient left the clinic with a titanium artificial heart and lived with it for 100 days. Earlier patients with this device remained only in the hospital.
The success of BiVACOR and similar devices signals their great potential to transform heart failure management. Thanks to its innovative design, the device also represents a long-term treatment alternative for patients who do not meet transplantation criteria (for example, due to age or other health problems).
Experts are optimistic but cautious about the technology, as it is in the early stages of clinical trials. The long-term functioning of the device, the final clinical outcomes for patients, and its financial cost are still unclear. However, the positive results achieved allow for the expansion of clinical trials and the widespread implementation of mechanical heart replacements in clinical practice.
Source: Bivacor
